S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
NASDAQ:TBPH

Theravance Biopharma - TBPH Stock Forecast, Price & News

$9.52
-0.31 (-3.15%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.50
$9.82
50-Day Range
$8.39
$9.83
52-Week Range
$6.10
$14.28
Volume
282,075 shs
Average Volume
1.00 million shs
Market Capitalization
$727.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.75

Theravance Biopharma MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
23.4% Upside
$11.75 Price Target
Short Interest
Bearish
13.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of Theravance Biopharma in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$142,259 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.75) to ($0.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

1045th out of 1,122 stocks

Pharmaceutical Preparations Industry

513th out of 551 stocks

TBPH stock logo

About Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Analyst Ratings Changes

A number of brokerages have issued reports on TBPH. HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Theravance Biopharma in a research report on Thursday, July 14th. SVB Leerink started coverage on Theravance Biopharma in a research report on Monday, May 23rd. They set an "outperform" rating and a $12.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $11.75.

Theravance Biopharma Trading Up 1.3 %

Shares of TBPH Stock opened at $9.83 on Wednesday. The firm has a fifty day moving average price of $9.04 and a 200 day moving average price of $9.34. The company has a market cap of $751.28 million, a P/E ratio of -7.23 and a beta of 0.69. Theravance Biopharma has a 12 month low of $6.10 and a 12 month high of $14.28.

Theravance Biopharma (NASDAQ:TBPH - Get Rating) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.06). During the same period in the previous year, the business posted ($0.80) EPS. On average, equities analysts forecast that Theravance Biopharma will post -0.75 EPS for the current year.

Insider Buying and Selling

In related news, SVP Richard A. Graham sold 15,086 shares of the business's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $8.79, for a total transaction of $132,605.94. Following the completion of the transaction, the senior vice president now owns 369,651 shares in the company, valued at $3,249,232.29. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 4.80% of the company's stock.

Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Stock News Headlines

Pre-market Movers: ARQQ, RAD, TBPH, ULCC, EGY…
Theravance Biopharma Misses Q1 EPS by 23c
Theravance Biopharma's Earnings Outlook
Theravance Biopharma Q1 2022 Earnings Preview
See More Headlines
Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Company Calendar

Last Earnings
8/04/2022
Today
8/17/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TBPH
Previous Symbol
NASDAQ:TBPHV
Fax
N/A
Employees
359
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.75
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+23.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
8 Analysts

Profitability

Net Income
$-199,430,000.00
Net Margins
-193.72%
Pretax Margin
-193.03%

Debt

Sales & Book Value

Annual Sales
$55.31 million
Book Value
($4.58) per share

Miscellaneous

Free Float
72,759,000
Market Cap
$727.59 million
Optionable
Optionable
Beta
0.69














TBPH Stock - Frequently Asked Questions

Should I buy or sell Theravance Biopharma stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TBPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBPH, but not buy additional shares or sell existing shares.
View TBPH analyst ratings
or view top-rated stocks.

What is Theravance Biopharma's stock price forecast for 2022?

8 brokerages have issued twelve-month price objectives for Theravance Biopharma's stock. Their TBPH share price forecasts range from $7.00 to $18.00. On average, they expect the company's share price to reach $11.75 in the next twelve months. This suggests a possible upside of 23.4% from the stock's current price.
View analysts price targets for TBPH
or view top-rated stocks among Wall Street analysts.

How have TBPH shares performed in 2022?

Theravance Biopharma's stock was trading at $11.05 at the beginning of the year. Since then, TBPH shares have decreased by 13.8% and is now trading at $9.52.
View the best growth stocks for 2022 here
.

When is Theravance Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our TBPH earnings forecast
.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.06. During the same quarter in the previous year, the company earned ($0.80) EPS.

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Park West Asset Management LLC (4.15%), FMR LLC (3.53%), Woodline Partners LP (2.94%), State Street Corp (1.96%), Chescapmanager LLC (1.53%) and Northern Trust Corp (0.78%). Insiders that own company stock include Brett K Haumann, Philip D Worboys, Rhonda Farnum, Richard A Graham and Vijay Sabesan.
View institutional ownership trends
.

How do I buy shares of Theravance Biopharma?

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $9.52.

How much money does Theravance Biopharma make?

Theravance Biopharma (NASDAQ:TBPH) has a market capitalization of $727.59 million and generates $55.31 million in revenue each year. The biopharmaceutical company earns $-199,430,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis.

How many employees does Theravance Biopharma have?

The company employs 359 workers across the globe.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The official website for the company is www.theravance.com. The biopharmaceutical company can be reached via phone at (650) 808-6000 or via email at investor.relations@theravance.com.

This page (NASDAQ:TBPH) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.